<code id='00E3AA8B24'></code><style id='00E3AA8B24'></style>
    • <acronym id='00E3AA8B24'></acronym>
      <center id='00E3AA8B24'><center id='00E3AA8B24'><tfoot id='00E3AA8B24'></tfoot></center><abbr id='00E3AA8B24'><dir id='00E3AA8B24'><tfoot id='00E3AA8B24'></tfoot><noframes id='00E3AA8B24'>

    • <optgroup id='00E3AA8B24'><strike id='00E3AA8B24'><sup id='00E3AA8B24'></sup></strike><code id='00E3AA8B24'></code></optgroup>
        1. <b id='00E3AA8B24'><label id='00E3AA8B24'><select id='00E3AA8B24'><dt id='00E3AA8B24'><span id='00E3AA8B24'></span></dt></select></label></b><u id='00E3AA8B24'></u>
          <i id='00E3AA8B24'><strike id='00E3AA8B24'><tt id='00E3AA8B24'><pre id='00E3AA8B24'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:focus    - browse:1

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge